KalVista Pharmaceuticals, Inc.
KALV
$13.16
$0.171.31%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -16.78% | -4.48% | 10.42% | 14.84% | 7.34% |
| Gross Profit | 16.78% | 4.48% | -10.42% | -14.84% | -7.34% |
| SG&A Expenses | 114.24% | 158.33% | 129.72% | 92.53% | 77.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.86% | 46.64% | 46.05% | 36.88% | 26.67% |
| Operating Income | -33.86% | -46.64% | -46.05% | -36.88% | -26.67% |
| Income Before Tax | -42.17% | -58.47% | -55.49% | -48.95% | -36.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -44.85% | -62.39% | -55.49% | -48.95% | -36.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.85% | -62.39% | -55.49% | -48.95% | -36.31% |
| EBIT | -33.86% | -46.64% | -46.05% | -36.88% | -26.67% |
| EBITDA | -33.97% | -46.85% | -46.28% | -37.05% | -26.76% |
| EPS Basic | -8.55% | -18.75% | -19.16% | -11.87% | -0.99% |
| Normalized Basic EPS | -6.42% | -15.97% | -19.23% | -12.81% | -2.25% |
| EPS Diluted | -8.55% | -18.75% | -19.16% | -11.87% | -0.99% |
| Normalized Diluted EPS | -6.42% | -15.97% | -19.23% | -12.81% | -2.25% |
| Average Basic Shares Outstanding | 34.84% | 37.02% | 30.12% | 30.82% | 31.78% |
| Average Diluted Shares Outstanding | 34.84% | 37.02% | 30.12% | 30.82% | 31.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |